Prospective evaluation of a dose prediction algorithm for intravenous tobramycin in adolescent and adult patients with cystic fibrosis

Therapeutic Drug Monitoring

Volumn 18, Issue 2, 1996, Pages 118-123

  Touw, D J ^a   Vinks, A A T M M ^b   Heijerman, H G M ^c   Bakker, W ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Hague Hospitals Central Pharmacy   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

Author keywords

Aminoglycosides; Cystic fibrosis; Pharmacokinetics; Serum concentration; Tobramycin

Indexed keywords

CHLORIDE; TOBRAMYCIN;

ADULT; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE CALCULATION; DRUG BLOOD LEVEL; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MALE; PREDICTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CYSTIC FIBROSIS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOBRAMYCIN;

EID: 0029991936     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199604000-00002     Document Type: Article

References (17)

1. De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Difference and clinical significance. Clin Pharmacokinet 1987;13:228-53.
2. Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985;1:238-43.
3. MacDonald NE, Anas N, Peterson RG, Schwartz RH, Brooks JG, Powell KR. Renal clearance of gentamicin in cystic fibrosis. J Pediatr 1983;103:985-9.
4. Hsu M-C, Aguila HA, Schmidt VL, Munzenberger PJ, Kauffman RE, Polgar G. Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatr Infect Dis 1984;3:526-9.
5. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105:117-24.
6. Horrevorts AM, Witte J de, Degener JE, et al. Tobramycin in patients with cystic fibrosis: adjustment in dosing interval for effective treatment. Chest 1987;92:844-8.
7. Thomassen MJ, Demko CA, Doershuk CF. Cystic fibrosis: a review of pulmonary infections and interventions. Pediatr Pulmonol 1987;3:334-51.
8. Product information: Obramycin, tobramycin. Eli Lilly and Company, Indianapolis, IN, 1992.
9. Horrevorts AM, Driessen OMJ, Michel MF, Kerrebijn KF. Pharmacokinetics of antimicrobial drugs in cystic fibrosis: aminoglycoside antibiotics. Chest 1988;94(suppl):120-5.
10. Mouton JW, Kerrebijn KF. Antibacterial therapy in cystic fibrosis. Med Clin North Am 1990;74:837-50.
11. Touw DJ, Vinks AATMM, Heijerman HGM, Bakker W. Validation of tobramycin monitoring in adolescents and adult patients with cystic fibrosis. Ther Drug Monit 1993;15: 52-9.
12. Touw DJ, Vinks AATMM, Heijerman HGM, Hermans J, Bakker W. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1994;16:125-31.
13. Newby MMJ, Keim NL, Brown DL. Body composition of adult cystic fibrosis patients and control patients as determined by densitometry, bioelectrical impedance, total-body electrical conductivity, skinfold measurements, and deuterium oxide dilution. Am J Clin Nutr 1990;52:209-13.
14. Vollaard EJ, Krugers Dagneaux PGLC. The serum concentration of aminoglycosides. In: Merkus FWHM, ed. The serum concentration of drugs. Clinical relevance, theory and practice. Amsterdam: Excerpta Medica, 1980:215-21.
15. Hallynck TH, Soep HH, Thomis JA, et al. Should clearance be normalized to body surface or to lean body mass? Br J Clin Pharmacol 1981;11:523-5.
16. Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988;35:542-78.
17. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9: 503-12.